Navigation Links
Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure
Date:10/1/2009

romising safety and efficacy of relaxin seen in these patients. The Pre-RELAX-AHF / RELAX-AHF study was designed and conducted in collaboration with Momentum Research, headed by Dr. Gad Cotter, a noted heart failure expert.

"Patients with acute heart failure remain a major clinical challenge with very high morbidity and mortality rates and limited treatment options," said John R. Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, Veterans Affairs Medical Center, San Francisco, and co-principal investigator of the studies. "The importance of this Fast Track designation is two-fold as it acknowledges a significant unmet medical need and recognizes relaxin's potential as an important treatment option for patients with AHF."

According to U.S. data, there are more than 3 million hospital discharges each year with heart failure as a diagnosis, with significant short-term rehospitalization and one-year mortality rates. It is the single largest expense to Medicare, accounting for more than $13 billion in hospitalization costs. The great majority of acute heart failure patients have fluid accumulation in the lungs (congestion) that causes shortness of breath (dyspnea) and other complications. For these patients, the current standard of care includes diuretics and vasodilators. Available agents from both of these classes of agents have been associated with renal impairment, hypotension and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure.


'/>"/>
SOURCE Corthera Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results and Additional Analyses From Study Show That Cortheras Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
2. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
3. Results From Study Show Promising Efficacy and Safety Results for Cortheras Relaxin in Acute Heart Failure
4. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
5. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
6. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
7. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
8. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
9. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
10. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
11. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... International Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased 3% ... sales decreased 4% as currency reduced sales growth by ... diluted share as reported (EPS) were $2.73, compared with ... , an increase of 9% over the prior-year ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 /PRNewswire/ ... a medical device company and manufacturer of the ... it has entered into non-exclusive Development Agreements with ... generation Tandem insulin pumps with the Dexcom G5 ... "Integrating Tandem,s next generation pump platform with ...
(Date:7/30/2015)... , July 30, 2015  OncoGenex Pharmaceuticals, Inc. ... report its second quarter 2015 financial results on Thursday, ... call and live webcast at 4:30 p.m. Eastern Time ... programs and a general corporate update. ... Relations page of the OncoGenex website at www.oncogenex.com ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... AXA Research Fund closed out its first year of existence. ... 13 million to various European research institutions.The purpose of the ... risks in the world by supporting cutting edge scientific research. ... million over five years, making it a major initiative in ...
... N.J., March 23 Each year in the United States ... myeloma. These new cases account for 10 percent of ... For several types of leukemia, the survival rate has ... James M. Golubieski, president of Foundation Venture Capital Group, LLC, ...
Cached Medicine Technology:First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 2First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 3Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
(Date:7/31/2015)... ... ... Like nearly every other form of surgery, it shouldn't come as a ... less intrusive and painful. Leading these advances in the United States has been ... as the only doctor in the United States who is qualified to practice, and ...
(Date:7/31/2015)... ... ... The Heart Fit Clinic has increased a patient's fitness level 60 percent ... beats versus 100 beats, this is a big deal," says Diamond Fernandes, director of ... patients with heart disease," he adds. People with angina are able to do a ...
(Date:7/31/2015)... ... July 31, 2015 , ... Burnaby sports physiotherapy clinic, Absolute ... understanding and treatment of ankle sprains. A common sports injury, ankle sprains are ... dangerous if the condition augments and causes more disruption. Absolute PhysioCare’s blog discusses ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 ... announce that they are the latest recipients of the Center of Clinical Excellence ... of the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair ...
(Date:7/31/2015)... ... ... is a reputable source of authentic USA vs. Australia tickets at Ford Field ... Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World Cup ... was awarded the Golden Ball as the best player of the 2015 Women's World Cup. ...
Breaking Medicine News(10 mins):Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... Health Care for All Depends on Adequate RN StaffingSILVER SPRING, ... American Nurses, AFL-CIO, pledged to redouble their efforts to secure ... Schakowsky (D-IL) -- that would make federal RN staffing ratios ... Nurses Week, I can think of no better gift for ...
... at American College of Obstetricians and Gynecologists, 57th Annual ... Surgical, Inc., a medical device company that has developed ... technology, released results from a preclinical study demonstrating that ... improved fascia incision healing in an in vivo model ...
... 2009 In a letter to the Editor of the ... by Elsevier, S. Lefebvre and J.S. Weese from the University ... MRSA and C.difficile could be passed between pet ... C. difficile may have been transferred to the ...
... blood clots are often recommended to stop these medications ... However, interruption of these medications can place patients at ... by Shai Friedland at the VA Palo Alto hospital ... without interrupting anticoagulation. Their study will be published on ...
... Elsevier, the world,s leading publisher of scientific, technical, ... Walsh, MSc, FACP, FRCP (Edin) on receiving the ... Project on Death in America (PDIA) Palliative Medicine ... AAHPM 2009 Annual Assembly on March 26. , ...
... Work, Money and the EconomySeven out of 10 ... 7 Economic pressures are having an increasing ... to a new survey by the American Psychological ... reporting significant stress related to work, money, housing ...
Cached Medicine News:Health News:UAN Hails Reintroduction of Federal RN Staffing Ratio Bill and Vows to Work for Passage 2Health News:PEAK Surgical Announces Positive Fascia Incision Healing Results From Preclinical Study of PEAK PlasmaBlade(TM) for Gynecologic Surgery 2Health News:PEAK Surgical Announces Positive Fascia Incision Healing Results From Preclinical Study of PEAK PlasmaBlade(TM) for Gynecologic Surgery 3Health News:PEAK Surgical Announces Positive Fascia Incision Healing Results From Preclinical Study of PEAK PlasmaBlade(TM) for Gynecologic Surgery 4Health News:PEAK Surgical Announces Positive Fascia Incision Healing Results From Preclinical Study of PEAK PlasmaBlade(TM) for Gynecologic Surgery 5Health News:Transmission of MRSA and Clostridium difficile through dogs 2Health News:Author Declan Walsh honored with National Leadership Award in Palliative Medicine 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 3
... Size: 3.0 x 7.5 x ... Scleral Sponge II line designed by ... material is a closed cell sponge ... are soft with rounded edges to ...
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Thin silicone pad implant. Indications: For closing scleral ruptures. Overall length: 7.8 mm....
... mm. Half oval. The original Scleral Sponge II ... been modified by Dr. Joseph Olk with this ... cell sponge which is non-toxic and non-antigenic. Implants ... intrusion. These implants are packaged sterile and sold ...
Medicine Products: